Vitamin D3 supplementation and body composition in persons with obesity and type 2 diabetes in the UAE: A randomized controlled double-blinded clinical trial.

Plain-language guide to PMID 25892603 (2016): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 2 participants.

Key Facts

PMID: 25892603
Journal: Clinical nutrition (Edinburgh, Scotland)
Year: 2016
Study type: Randomized Controlled Trial
Authors: Sadiya A et al. (8 authors)
DOI: 10.1016/j.clnu.2015.02.017
Registered trial: NCT02101151

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The co-existence of vitamin D deficiency with obesity and type 2 diabetes is highly prevalent in the United Arab Emirates.

Who Took Part

The study group was 2 participants.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Serum 25-hydroxy vitamin D (S-25(OH)D), anthropometric data, and life-style factors such as diet and sunlight exposure were measured.

What Was Measured

Topics PubMed links to this paper include Aftercare, Body Composition, Cholecalciferol, Diabetes Mellitus, Type 2, Dietary Supplements, Obesity and Parathyroid Hormone.

Author keywords: Type 2 diabetes, United Arab Emirates and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Vitamin D, K2, Magnesium and Zinc in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.